Nicole Sweeny Sells 1,862 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Nicole Sweeny sold 1,862 shares of KalVista Pharmaceuticals stock in a transaction on Friday, April 17th. The stock was sold at an average price of $20.22, for a total value of $37,649.64. Following the transaction, the insider owned 51,391 shares in the company, valued at approximately $1,039,126.02. This represents a 3.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Nicole Sweeny also recently made the following trade(s):

• On Monday, February 23rd, Nicole Sweeny sold 3,975 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $15.57, for a total value of $61,890.75.

KalVista Pharmaceuticals Stock Down 6.9%

NASDAQ KALV opened at $19.43 on Wednesday. KalVista Pharmaceuticals, Inc. has a 52 week low of $9.83 and a 52 week high of $21.31. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. The business’s fifty day simple moving average is $17.59 and its 200-day simple moving average is $15.28. The firm has a market cap of $995.20 million, a PE ratio of -4.92 and a beta of -0.40.

KalVista Pharmaceuticals News Summary

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Analysts have raised price targets and reiterated buy ratings (HC Wainwright, Stifel, Needham), which supports upside expectations relative to the current price. Read More.
• Positive Sentiment: Large institutional buying reported in recent quarters (Vanguard, State Street, Tudor, Vestal Point, Parkman Healthcare) signals conviction from long‑term investors and can underpin the stock if fundamentals progress. Read More.
• Neutral Sentiment: Company fundamentals and technicals are supportive: strong liquidity (high current/quick ratios) and the 50‑day/200‑day moving averages sit below recent trades — helpful background but not an immediate catalyst.
• Negative Sentiment: Multiple insiders sold shares on April 17 (CEO Benjamin Palleiko sold 9,550 shares; CFO Brian Piekos and others sold smaller blocks). Filings state the sales were to cover tax withholding on vested awards, but the concentrated insider selling is creating near‑term downward pressure and investor concern. Read More.

Analyst Upgrades and Downgrades

KALV has been the topic of several research analyst reports. Stifel Nicolaus boosted their price objective on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Needham & Company LLC boosted their price objective on shares of KalVista Pharmaceuticals from $35.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. Citizens Jmp reduced their price objective on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a report on Thursday, March 26th. Finally, Wall Street Zen lowered shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $32.60.

Institutional Trading of KalVista Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company raised its holdings in KalVista Pharmaceuticals by 5.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 14,626 shares of the specialty pharmaceutical company’s stock valued at $165,000 after buying an additional 818 shares during the period. BNP Paribas Financial Markets increased its stake in KalVista Pharmaceuticals by 47.0% during the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after purchasing an additional 1,292 shares during the period. Rhumbline Advisers increased its stake in KalVista Pharmaceuticals by 2.8% during the second quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company’s stock worth $615,000 after purchasing an additional 1,458 shares during the period. Charles Schwab Investment Management Inc. increased its stake in KalVista Pharmaceuticals by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 324,369 shares of the specialty pharmaceutical company’s stock worth $5,239,000 after purchasing an additional 2,402 shares during the period. Finally, Profund Advisors LLC increased its stake in KalVista Pharmaceuticals by 25.9% during the third quarter. Profund Advisors LLC now owns 12,613 shares of the specialty pharmaceutical company’s stock worth $154,000 after purchasing an additional 2,593 shares during the period.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.